Pediatric Gastrointestinal Outcomes During the Post-Acute Phase of COVID-19
Dazheng Zhang,Ronen Stein,Yiwen Lu,Ting Zhou,Yuqing Lei,Lu Li,Jiajie Chen,Jonathan Arnold,Michael Becich,Elizabeth A Chrischilles,Cynthia H. Chuang,Dimitri A. Christakis,Daniel Fort,Carol R. Geary,Mady Hornig,Rainu Kaushal,David M. Liebovitz,Abu S M Mosa,Hiroki Morizono,Parsa Mirhaji,Jennifer L. Dotson,Claudia Pulgarin,Marion R. Sills,Srinivasan Suresh,David A. Williams,Robert N. Baldassano,Christopher B. Forrest,Yong Chen,RECOVER Initiative
DOI: https://doi.org/10.1101/2024.05.21.24307699
2024-07-09
Abstract:Importance: The profile of gastrointestinal (GI) outcomes that may affect children in post-acute and chronic phases of COVID-19 remains unclear.
Objective: To investigate the risks of GI symptoms and disorders during the post-acute phase (28 days to 179 days after SARS-CoV-2 infection) and the chronic phase (180 days to 729 days after SARS-CoV-2 infection) in the pediatric population.
Design: We used a retrospective cohort design from March 2020 to Sept 2023.
Setting: twenty-nine healthcare institutions.
Participants: A total of 413,455 patients aged not above 18 with SARS-CoV-2 infection and 1,163,478 patients without SARS-CoV-2 infection.
Exposures: Documented SARS-CoV-2 infection, including positive polymerase chain reaction (PCR), serology, or antigen tests for SARS-CoV-2, or diagnoses of COVID-19 and COVID-related conditions.
Main Outcome(s) and Measure(s): Prespecified GI symptoms and disorders during two intervals: post-acute phase and chronic phase following the documented SARS-CoV-2 infection. The adjusted risk ratio (aRR) was determined using a stratified Poisson regression model, with strata computed based on the propensity score.
Results: Our cohort comprised 1,576,933 patients, with females representing 48.0% of the sample. The analysis revealed that children with SARS-CoV-2 infection had an increased risk of developing at least one GI symptom or disorder in both the post-acute (8.64% vs. 6.85%; aRR 1.25, 95% CI 1.24-1.27) and chronic phases (12.60% vs. 9.47%; aRR 1.28, 95% CI 1.26-1.30) compared to uninfected peers. Specifically, the risk of abdominal pain was higher in COVID-19 positive patients during the post-acute phase (2.54% vs. 2.06%; aRR 1.14, 95% CI 1.11-1.17) and chronic phase (4.57% vs. 3.40%; aRR 1.24, 95% CI 1.22-1.27).
Conclusions and Relevance:
In the post-acute phase or chronic phase of COVID-19, the risk of GI symptoms and disorders was increased for COVID-positive patients in the pediatric population.
Infectious Diseases (except HIV/AIDS)